Oramed Pharmaceuticals Inc. (ORMP)

Oramed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019
Revenue	0.67	1.34	2.7	2.7	2.71	2.7
Revenue Growth (YoY)	-75.06%	-50.43%	0%	-0.26%	0.26%	10.37%
Cost of Revenue	0	0	0	0	0	0.09
Gross Profit	0.67	1.34	2.7	2.7	2.71	2.61
Selling, General & Admin	8.47	8.14	15.66	5.94	4.23	3.72
Research & Development	5.72	8.97	27.64	20.99	10.24	13.52
Operating Expenses	14.2	17.11	43.3	26.93	14.47	17.24
Operating Income	-13.52	-15.77	-40.6	-24.22	-11.76	-14.63
Interest Expense / Income	-0.86	2.04	0	0.01	0.44	0.49
Other Expense / Income	-23.12	-23.33	-4.14	-1.99	-0.69	-1.06
Pretax Income	10.46	5.53	-36.46	-22.24	-11.51	-14.06
Income Tax	0	0	0.1	0	0	0.3
Net Income	10.46	5.53	-36.56	-22.24	-11.51	-14.36
Shares Outstanding (Basic)	41	40	39	28	21	17
Shares Outstanding (Diluted)	42	41	39	28	21	17
Shares Change	3.80%	4.02%	36.98%	38.65%	17.63%	17.28%
EPS (Basic)	0.26	0.14	-0.94	-0.78	-0.56	-0.82
EPS (Diluted)	0.26	0.14	-0.94	-0.78	-0.56	-0.82
Free Cash Flow	-6.28	-10.55	-28.39	-21.56	-12.52	-12.96
Free Cash Flow Per Share	-0.15	-0.26	-0.73	-0.76	-0.61	-0.74
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	96.67%
Operating Margin	-2006.38%	-1176.79%	-1501.96%	-896.15%	-433.84%	-541.29%
Profit Margin	1551.34%	412.31%	-1352.61%	-822.72%	-424.76%	-531.08%
Free Cash Flow Margin	-931.60%	-787.24%	-1050.31%	-797.48%	-462.07%	-479.28%
EBITDA	9.81	7.76	-36.4	-22.15	-11.06	-13.56
EBITDA Margin	1455.34%	578.96%	-1346.76%	-819.57%	-408.12%	-501.74%
Depreciation & Amortization	0.22	0.2	0.06	0.08	0.01	0.01
EBIT	9.59	7.56	-36.46	-22.23	-11.07	-13.57
EBIT Margin	1423.44%	564.33%	-1348.91%	-822.42%	-408.38%	-502.03%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).